FDA OKs 8-Week Mavyret for Hepatitis C FDA OKs 8-Week Mavyret for Hepatitis C

Glecaprevir/pibrentasvir is the first HCV treatment of this duration approved for genotypes 1 through 6 in previously untreated adults without cirrhosis.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news